Business
National Institutes of Health Licensing Agreement
National Institutes of Health Licensing Agreement.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n \n11 May 2010\n\n Scancell Holdings Plc \n\n ('Scancell') \n\n National Institutes of Health Licensing Agreement \n\nScancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer\nvaccines, is pleased to announce it has signed a worldwide non-exclusive\nlicensing agreement with the National Institutes of Health (`NIH'), a division\nof the U.S. Department of Health and Human Services, for use of the melanoma\nantigens TRP-2 and gp100, key components of Scancell's lead ImmunoBody® vaccine\nfor melanoma, SCIB1.\n\nUnder the agreement, Scancell has agreed to pay the US Public Health Service an\nundisclosed upfront fee in addition to certain milestone fees and a royalty on\nfuture sales of SCIB1. Scancell will have the right to develop and\ncommercialise its ImmunoBody® vaccines for the treatment of melanoma in humans\nincorporating epitopes from these targets.\n\nImmunoBody® vaccines generate the high-avidity T-cells that kill cancer cells,\nwhich may overcome the current limitations of most cancer vaccines. Scancell is\nexpected to commence its Phase I clinical trials for SCIB1 in Q2 2010.\n\nDavid Evans, chairman of Scancell, commented:\n\n\"This agreement strengthens Scancell's IP position around SCIB1 and enables the\nCompany to move forward towards its proposed clinical trials of the melanoma\nvaccine.\"\n\nThe Directors of the issuer accept responsibility for this announcement.\n\n -ENDS- \n\nFor Further Information:\n\nDavid Evans, Chairman Scancell Holdings Plc + 44 774 008 4452 \n \nProfessor Lindy Durrant, CEO Scancell Holdings Plc + 44 207 245 1100 \n \nKirsty Corcoran/John Bick Hansard Communications + 44 207 245 1100 \n \nRoss Andrews / Tom Rowley Zeus Capital + 44 161 831 1512 \n\nAbout Scancell\n\nScancell is developing novel therapeutic vaccines for the treatment of cancer\nand infectious diseases based on its groundbreaking ImmunoBody® technology\nplatform. Scancell's first cancer vaccine SCIB1 is being developed for the\ntreatment of melanoma and is expected to enter clinical trials in 2010.\n\nTreating cancer by vaccination allows small non-toxic doses of a vaccine to be\nadministered to a patient, stimulating an immune response. Effective cancer\nvaccines need to target dendritic cells to stimulate both parts of the cellular\nimmune system; the helper cell system where inflammation is stimulated ...